SCHEMBL17558186

SCHEMBL17558186

CC(C)(C)OC(=O)NC(=NC(=O)O)N1CCC(CCN)CC1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.38
ACACA Q13085 1/20 0.38
KDM4E B2RXH2 1/20 0.37
PKM P14618 1/20 0.37
ITGB3 P05106 8/20 0.36
ITGA2B P08514 8/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
TSHR P16473 1/20 0.36
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
DRD2 P14416 1/20 0.33
SIRT2 Q8IXJ6 1/20 0.33
SIRT1 Q96EB6 1/20 0.33
SIRT3 Q9NTG7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17558184 1.00 ACACB (0.38) ACACBACACAKDM4EPKMITGB3
SCHEMBL19410256 0.91 ACACB (0.38) ACACBACACAKDM4EPKMITGB3
SCHEMBL17574398 0.90 ACACB (0.36) ACACBACACAKDM4EPKMITGB3
SCHEMBL28173828 0.90 ACACB (0.36) ACACBACACAKDM4EPKMITGB3
SCHEMBL19410259 0.85 MEN1 (0.36) KDM4EPKMALDH1A1KMT2AMEN1
SCHEMBL19410261 0.85 MEN1 (0.36) KDM4EPKMALDH1A1KMT2AMEN1
SCHEMBL7299678 0.81 ALDH1A1 (0.36) ACACBACACAKDM4EPKMITGB3
SCHEMBL17574380 0.81 ALDH1A1 (0.36) ACACBACACAKDM4EPKMITGB3
SCHEMBL9073870 0.81 ALDH1A1 (0.36) ACACBACACAKDM4EPKMITGB3
SCHEMBL19418991 0.80 ACACB (0.39) ACACBACACAKDM4EPKMITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3189047-B1 DIAMIDE MACROCYCLES THAT ARE FXIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-12-26 EP disclosed
US-10081623-B2 Diamide macrocycles that are FXIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-09-25 US disclosed
US-20170283403-A1 DIAMIDE MACROCYCLES THAT ARE FXIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-10-05 US disclosed
EP-3189047-A1 DIAMIDE MACROCYCLES THAT ARE FXIA INHIBITORS Bristol-Myers Squibb Company (US) 2017-07-12 EP disclosed
WO-2016036893-A1 DIAMIDE MACROCYCLES THAT ARE FXIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170283403-A1 DIAMIDE MACROCYCLES THAT ARE FXIA INHIBITORS TFPI, TFPI2, F2 ACACB 3280/4885ACACA 2699/4885KDM4E 642/4885
US-10081623-B2 Diamide macrocycles that are FXIa inhibitors TFPI, TFPI2, F2 ACACB 3280/4885ACACA 2699/4885KDM4E 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.